Boc-Tyr(Bzl)-OHCAS# 2130-96-3 |
- Cisplatin
Catalog No.:BCN1552
CAS No.:14283-03-5
- Z-VAD-FMK
Catalog No.:BCC1126
CAS No.:187389-52-2
- Z-WEHD-FMK
Catalog No.:BCC1139
CAS No.:210345-00-9
- Z-LEHD-FMK
Catalog No.:BCC5117
CAS No.:210345-04-3
- AZ 10417808
Catalog No.:BCC2356
CAS No.:331645-84-2
- Apoptosis Activator 2
Catalog No.:BCC2099
CAS No.:79183-19-0
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 2130-96-3 | SDF | Download SDF |
| PubChem ID | 294897 | Appearance | Powder |
| Formula | C21H25NO5 | M.Wt | 371.4 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | 2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-(4-phenylmethoxyphenyl)propanoic acid | ||
| SMILES | CC(C)(C)OC(=O)NC(CC1=CC=C(C=C1)OCC2=CC=CC=C2)C(=O)O | ||
| Standard InChIKey | ZAVSPTOJKOFMTA-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C21H25NO5/c1-21(2,3)27-20(25)22-18(19(23)24)13-15-9-11-17(12-10-15)26-14-16-7-5-4-6-8-16/h4-12,18H,13-14H2,1-3H3,(H,22,25)(H,23,24) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Boc-Tyr(Bzl)-OH Dilution Calculator
Boc-Tyr(Bzl)-OH Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.6925 mL | 13.4626 mL | 26.9251 mL | 53.8503 mL | 67.3129 mL |
| 5 mM | 0.5385 mL | 2.6925 mL | 5.385 mL | 10.7701 mL | 13.4626 mL |
| 10 mM | 0.2693 mL | 1.3463 mL | 2.6925 mL | 5.385 mL | 6.7313 mL |
| 50 mM | 0.0539 mL | 0.2693 mL | 0.5385 mL | 1.077 mL | 1.3463 mL |
| 100 mM | 0.0269 mL | 0.1346 mL | 0.2693 mL | 0.5385 mL | 0.6731 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Boc-Tyr(Bzl)-OH
- Tetrahymanol acetate
Catalog No.:BCN6933
CAS No.:2130-22-5
- Tetrahymanol
Catalog No.:BCN6934
CAS No.:2130-17-8
- (S)-(+)-Abscisic acid
Catalog No.:BCN2210
CAS No.:21293-29-8
- Purvalanol B
Catalog No.:BCC3887
CAS No.:212844-54-7
- Purvalanol A
Catalog No.:BCC5654
CAS No.:212844-53-6
- Cowaxanthone B
Catalog No.:BCN3892
CAS No.:212842-64-3
- Kumokirine
Catalog No.:BCN2011
CAS No.:21284-20-8
- Kuramerine
Catalog No.:BCN1806
CAS No.:21284-19-5
- Ramage Linker,Fmoc-Suberol
Catalog No.:BCC2834
CAS No.:212783-75-0
- NG 52
Catalog No.:BCC1798
CAS No.:212779-48-1
- Xanthiazone
Catalog No.:BCN2544
CAS No.:212701-97-8
- PD184352 (CI-1040)
Catalog No.:BCC1112
CAS No.:212631-79-3
- Org 37684
Catalog No.:BCC6291
CAS No.:213007-95-5
- Ceanothic acid
Catalog No.:BCN4918
CAS No.:21302-79-4
- [Phe1Ψ(CH2-NH)Gly2]Nociceptin(1-13)NH2
Catalog No.:BCC5701
CAS No.:213130-17-7
- RITA (NSC 652287)
Catalog No.:BCC2238
CAS No.:213261-59-7
- H-Pro-OMe.HCl
Catalog No.:BCC3022
CAS No.:2133-40-6
- 15,18-Dihydroxyabieta-8,11,13-trien-7-one
Catalog No.:BCN1495
CAS No.:213329-45-4
- 18-Nor-4,15-dihydroxyabieta-8,11,13-trien-7-one
Catalog No.:BCN1494
CAS No.:213329-46-5
- 1-Methyl-L-tryptophan
Catalog No.:BCN8341
CAS No.:21339-55-9
- Ercalcidiol
Catalog No.:BCC1555
CAS No.:21343-40-8
- Flumethasone
Catalog No.:BCC8986
CAS No.:2135-17-3
- Drim-7-ene-11,12-diol acetonide
Catalog No.:BCN4919
CAS No.:213552-47-7
- 5-Iodo-A-85380, 5-trimethylstannyl N-BOC derivative
Catalog No.:BCC7102
CAS No.:213766-21-3
A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid receptor agonists and neurokinin 1 receptor antagonists.[Pubmed:18266313]
J Med Chem. 2008 Mar 13;51(5):1369-76.
A series of bifunctional peptides with opioid agonist and substance P antagonist bioactivities were designed with the concept of overlapping pharmacophores. In this concept, the bifunctional peptides were expected to interact with each receptor separately in the spinal dorsal horn where both the opioid receptors and the NK1 receptors were found to be expressed, to show an enhanced analgesic effect, no opioid-induced tolerance, and to provide better compliance than coadministration of two drugs. Compounds were synthesized using a two-step combinatorial method for C-terminal modification. In the method, the protected C-terminal-free carboxyl peptide, Boc-Tyr( tBu)- d-Ala-Gly Phe-Pro-Leu-Trp(Boc)-OH, was synthesized as a shared intermediate using Fmoc solid phase chemistry on a 2-chlorotrityl resin. This intermediate was esterified or amidated in solution phase. The structure-activity relationships (SAR) showed that the C-terminus acted as not only a critical pharmacophore for the substance P antagonist activities, but as an address region for the opioid agonist pharmacophore that is structurally distant from the C-terminal. Among the peptides, H-Tyr- d -Ala-Gly-Phe-Pro-Leu-Trp-NH-Bzl ( 3) demonstrated high binding affinities at both delta and mu receptors ( K i = 10 and 0.65 nM, respectively) with efficient agonist functional activity in the mouse isolated vas deferens (MVD) and guinea pig isolated ileum (GPI) assays (IC 50 = 50 and 13 nM, respectively). Compound 3 also showed a good antagonist activity in the GPI assay with substance P stimulation ( K e = 26 nM) and good affinity for the hNK1 receptor ( K i = 14 nM). Consequently, compound 3 is expected to be a promising and novel type of analgesic with bifunctional activities.
